How about Federal Pharmaceutical, Federal Pharmaceutical Drug Packaging is not tired

Hello! Federal Pharmaceutical International Holdings**** is a Hong Kong listed company, and the chairman of the group, Choi Jinle, is a Hong Kong native.

Federated Pharmaceuticals was founded in Hong Kong in 1990. In 1994, it invested hundreds of millions of Hong Kong dollars to establish Zhuhai Federal Pharmaceutical Co., Ltd., with advanced pharmaceutical technology, scientific management, excellent service, and enthusiasm for serving the health of the Chinese people, providing diversified products, especially antimicrobial products, as well as APIs and intermediates of the products, and fully promoting the development of China's pharmaceutical and health undertakings. Federated Pharmaceutical has 6 production bases, including Hong Kong Federal Pharmaceutical Factory (preparation), Zhuhai Federal Pharmaceutical Co., Ltd. (raw materials), Zhuhai Federal Pharmaceutical Co., Ltd. Zhongshan Branch (preparation), Federal Pharmaceutical Jinyi Capsule Factory (hollow capsule), Federal Pharmaceutical (Chengdu) **** (intermediates), Federal Pharmaceutical (Inner Mongolia) **** (intermediates).

Federal Pharmaceutical integrates drug R&D, production and operation, and integrates the production of pharmaceutical intermediates, APIs, pharmaceutical preparations and pharmaceutical packaging materials from biological fermentation, realizes a vertically integrated production and operation model, and lays a solid foundation for the excellent product quality of Federal Pharmaceutical with a high-quality after-sales service network, perfect market information feedback system and rigorous quality assurance system. On June 15, 2007, Federated Pharmaceutical International Holdings was successfully listed in Hong Kong, marking a new development platform for Federated Pharmaceutical, which expanded a broad space for the rapid expansion of the corporate brand based in Hong Kong, radiating the world, and realizing the rapid expansion of the corporate brand. Federal Pharmaceuticals has world-class production facilities.

The annual production capacity is 1.5 billion capsules, 100 million tablets, 100 million granules, 20 million suspensions, 30 million bottles of oral liquid, 30 million bottles of powder injections, 13 million ointments, 50 tons of freeze-dried raw materials, 15 million eye drops, and 35 million injections. Federal Pharmaceutical has been leading in many products, such as the National Torch Program Key High-tech Enterprise, Guangdong High-tech Enterprise, China Pharmaceutical Professional Postdoctoral Research Station, China's Top 100 Pharmaceutical Industry, and Guangdong Province Advanced Collective, each of which is well-known in the industry, which fully proves the comprehensive strength of Federal Pharmaceutical; The first batch of pharmaceutical companies in China that all dosage forms of the whole plant have passed the national GMP certification at one time, the research and development of more than 160 kinds of drugs, the acquisition of hundreds of pharmaceutical approvals, and each valuable golden signboard fully reflects the leading level of Federal Pharmaceutical. As always, Federated Pharmaceutical adheres to the commitment of "making life more valuable", and is committed to promoting the development of China's medical and health industry and providing more high-quality and efficient pharmaceutical products for the society.

If you want to work in the quality inspection department, it is best to understand their corporate culture and work system. They have a strict hierarchy, detailed job assignments, and long overtime hours. In general, their management system in all aspects is suitable for the company's management and not suitable for employees' self-development and improvement, once employees leave the company, they will be very uncomfortable with other companies for employment, and they are more white than other practitioners with the same experience.

To be honest, I didn't have a good impression of this company at the beginning, and when we went to the interview, the company's HR didn't arrange the interview time. Many people go all the way to the interview by car but wait for five or six hours until they are about to get off work before they hurriedly arrange the interview, only interview the person in front of them and stop the interview, all go back and wait for the results, which shows that they do not attach much importance to employees. The turnover rate of their company is also quite high, and the replacement of new and old employees is fast, on the one hand, there is a lot of overtime, and on the other hand, the quality inspection work arrangement is very simple and cannot learn things.

It's a family business; The boss's surname is Cai, and the company expanded quickly and was listed in Hong Kong.

I mainly do antibiotics, and recently I seem to be saying that I want to do insulin.

There are several factories in Zhuhai, Zhongshan, Sichuan and Inner Mongolia.

Overall, the company is just like the boss's name "Jinle", hehe, only knows how to make money. There is a clear hierarchy of employees in the factory. The working atmosphere is not good.

Hello, federal pharmaceutical drug packaging is tired, the answer to this question actually needs to be seen on a case-by-case basis. On the one hand, pharmaceutical packaging is a very important part of federal pharmaceuticals, because it is directly related to the quality and safety of drugs. Therefore, Federal Pharmaceutical requires very strict control and management in the design, material selection, production process and other aspects of drug packaging, which will undoubtedly increase a certain amount of work and cost.

On the other hand, if the design and production of pharmaceutical packaging are reasonable, it can improve the convenience and user experience of drugs, thereby bringing more market competitiveness and commercial benefits to enterprises. In addition, the investment and efforts of Federal Pharmaceutical in pharmaceutical packaging can also enhance the brand image and public trust of the company, and lay a solid foundation for the long-term development of the company.

Therefore, in general, although the federal pharmaceutical drug packaging will increase a certain amount of work and cost, if it can be properly designed and managed, it will have a very positive impact on the company's lead development and brand image.

Hello, federal pharmaceutical drug packaging is not tired, this is a false Lu needs to be analyzed on a case-by-case basis. On the one hand, drug packaging is an important part of drug production, and it must be packaged in strict accordance with relevant laws, regulations and standards to ensure the quality and safety of drugs. This may increase the burden and cost of some drug manufacturers, but it is necessary to protect the health and safety of the public.

On the other hand, if the drug packaging is too complex or cumbersome, it may also increase the difficulty and inconvenience of users, and even affect the efficacy of the drug. Therefore, pharmaceutical packaging should be as simplified and convenient to use as possible on the premise of ensuring quality and safety, so that it is easier for users to understand and operate. In short, pharmaceutical packaging is a problem that needs to balance various factors, and it needs to be as user-friendly as possible under the premise of ensuring the quality and safety of drugs in the differential zone.

In China, the number of diabetic patients has reached nearly 100 million, the incidence rate has exceeded 10%, and the domestic diabetes drug market has exceeded 10 billion yuan. According to incomplete statistics, the market capacity of insulin has also exceeded 5 billion yuan, with an annual growth rate of more than 20%. In China's diabetes market, Novo Nordisk and Eli Lilly occupy most of the market share, while domestic companies have done little.

Federated Pharmaceuticals hopes to provide doctors and consumers with high-quality and cost-effective insulin through technological advantages and cost control. Following the successful production of insulin in the first half of 2010, Federated Pharmaceutical received three additional recombinant human insulin production approvals from the State Food and Drug Administration in January 2011. At this point, the genetically recombinant human insulin of Federal Pharmaceutical, the Yasling series family (Yasling R, Yasling N, Yasling 30R, Yasling 50R) has taken shape and will soon enter mass production and put on the market.

Federal Pharmaceutical has realized an integrated production line from insulin raw materials to preparations, which can avoid the pollution that may be encountered in the long-distance transportation of insulin raw materials and can control the product quality well. In addition, the preparation production line of Federal Yousling adopts imported automatic cartridge refill production and filling lines. Most of the equipment is from Germany, France, Italy and other countries, and it is the most advanced equipment in the world in the production of similar products of recombinant human insulin, ensuring stable product quality, safety and effectiveness.

At the beginning of R&D, Federated Pharmaceutical aimed at the high-end, and the recombinant human insulin series products produced by Yasling (Yasling R, Yasling N, Yasling 30R, Yasling 50R) are the most advanced Pichia pastoris expression system, and the drug has the advantages of less impurities, conducive to purification, and small clinical side effects. Federal Pharma is the only company with the relevant process and has been granted a 4-year technical and product protection period. Federated Pharmaceutical will continue to invest 1 billion yuan to expand the insulin market in China, producing insulin and insulin analogues to meet the needs of diabetic patients across the country.

Founded in Hong Kong in 1990, Federated Pharmaceutical has become a large-scale modern high-tech enterprise integrating drug R&D, production and sales. It is mainly engaged in the production and sales of pharmaceutical preparations, raw materials, pharmaceutical intermediates and capsules. The company has more than 31,000 employees and annual sales of more than 8 billion yuan.

Now it has five production bases: Hong Kong Preparation Factory, Zhuhai Raw Material Factory, Zhongshan Preparation Factory, Chengdu Raw Material Factory, Kaiping Capsule Factory and Inner Mongolia Intermediate Factory. It is the first batch of pharmaceutical companies in China to pass the national GMP certification for all dosage forms in the whole plant at one time, and some products are applying for European COS and US FDA certification.

Summary. Hello, dear! Federal Zuofukang is produced by Zhuhai Federal Pharmaceutical Co., Ltd. **** Zhongshan Branch; This product is suitable for the following mild and moderate infections caused by susceptible bacteria:

1.Respiratory infections: acute bronchitis, chronic bronchitis, acute exacerbation of chronic bronchitis, diffuse bronchiolitis, bronchiectasis with infection, pneumonia, pharyngitis, tonsillitis (peritonsillar abscess).

2.Urinary tract infections: pyelonephritis, complicated urinary tract infections, etc.

3.Reproductive system infection: prostatitis, epididymitis, uterine infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected).

4.**Soft tissue infections: infectious impetigo, cellulitis, lymphangitis (nodalitis), subcutaneous abscess, perianal abscess, etc.

5.Intestinal infection: bacillary dysentery, infectious enteritis, Salmonella enteritis, typhoid fever and paratyphoid fever, etc.

6.Other infections: trauma, burns and postoperative wound infections, abdominal infections (combined with metronidazole if necessary), mastitis, cholecystitis, cholangitis, bone and joint infections, and ENT infections.

Hello, dear! Federal Zuofukang is produced by Zhuhai Federal Pharmaceutical Co., Ltd. **** Zhongshan Branch; This product is suitable for the following mild and moderate infections caused by sensitive bacteria: 1

Respiratory infections: acute bronchitis, chronic bronchitis, acute exacerbation of chronic bronchitis, diffuse bronchiolitis, bronchiectasis with infection, pneumonia, pharyngitis, tonsillitis (peritonsillar abscess). 2.

Urinary tract infections: pyelonephritis, complicated urinary tract infections, etc. 3.

Reproductive system infection: prostatitis, epididymitis, uterine infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected). 4.

**Soft tissue infection: infectious impetigo, cellulitis, drenching (nodalitis), subcutaneous abscess, perianal abscess, etc. 5.

Intestinal infection: bacillary dysentery, infectious enteritis, enteritis of the genus Salmonella, typhoid fever and paratyphoid fever, etc. 6.

Other infections: trauma, burns and postoperative wound infections, abdominal infections (combined with metronidazole if necessary), mastitis, cholecystitis, cholangitis, bone and joint infections, and ENT infections.